OUR PIPELINE
Transforming Cancer Care: ONIRIA’s Path from Innovative Research to Life-Changing Therapies
As we advance through preclinical studies focused on the groundbreaking capabilities of ONR-001, we are poised to embark on our initial clinical trials in 2024.
This marks a pivotal moment in our mission to harness epigenetic mechanisms, offering a promising avenue for treating cancer across all stages with a singular, innovative approach.
| Product | INDICATIONS | TARGET DISCOVERY |
HIT-TO-LEAD | LEAD OPTIMIZATION |
CANDIDATE SELECTION |
PRE-CLINICAL REGULATORY |
PHASE I/IIA |
PHASE II | PHASE III | REGULATORY SUBMISSION |
STATUS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ONR-001 TET2 ACTIVATOR |
MELANOMA, AML, MDS, CRC |
|
CANDIDATE SELECTION & PRE-CLINICAL NON-REGULATORY STUDIES |
||||||||
| ONR-002 TET2 INHIBITOR |
ONCOLOGY |
|
HIT-TO-LEAD | ||||||||
| ONR-003 TET2 PROTAC |
ONCOLOGY |
|
HIT-TO-LEAD | ||||||||
| NEW TARGETS |
ONCOLOGY |
|
DISCOVERY | ||||||||
| ONR-004 TET2 ACTIVATOR |
AGING |
ACTIVELY LOOKING FOR A CO-DEVELOPMENT PROGRAM |
CANDIDATE SELECTION & PRE-CLINICAL NON-REGULATORY STUDIES |
||||||||
| Product | INDICATIONS | TARGET DISCOVERY |
HIT-TO-LEAD | LEAD OPTIMIZATION |
CANDIDATE SELECTION |
PRE-CLINICAL REGULATORY |
PHASE I/IIA |
PHASE II | PHASE III | REGULATORY SUBMISSION |
STATUS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOMARKER 5hmC |
TET2 ACTIVATOR & INHIBITOR |
|
DEVELOPMENT | ||||||||
